Back to search

National and Kapodistrian University of Athens

Κλινικές και δομικές μεταβολές μετά από θεραπευτική παρέμβαση με αναστολέα του μετατρεπτικού ενζύμου της αγγειοτασίνης στην υπερτροφία αριστεράς κοιλίας λόγω υπέρτασης

Abstract

dc:description

Background: Arterial hypertension is a worldwide leading cause of cardiovascular morbidity and its frequency expands in the aging population. A rise of 20 mmHg in systolic blood pressure (SBP) and 10mmHg in diastolic blood pressure (DBP) doubles mortality caused by myocardial infraction and even more by stroke. In the contrary a fall in blood pressure benefits cardiovascular outcomes. Even if may considered simple, appears that arterial hypertension is difficult to be diagnosed and well controlled since one over two people with hypertension ignore their disease and most important one over two doesn’t get the appropriate therapy. Left ventricular hypertrophy (LVH) is the hall mark of the target organ damage mediated by arterial hypertension. Presence of such change in left ventricular geometry rises the prevalence of coronary artery disease, heart failure, stroke and cardiovascular mortality. Myocardium contains muscle fibers (30%) but also interstitial tissue (70%) and vessels. LVH alters the size of the muscle fibers and the structure of the interstitial space. Specific peptidases called matrix metalloproteinases (MMPs) are responsible for the remodeling by degrading collagen fibers under control of their tissue inhibitors (TIMPs). In LVH there is a shift of this balance towards collagen synthesis by a dominant action of the TIMPs. On the contrary, with regression of the hypertrophy MMPs have the key role by degrading the accumulated excess of collagen. MMP2 and MMP3 typically fall in LVH. MMP9 has a lesser ability to degrade collagen and exhibits a pro fibrotic action. NT pro BNP is a peptide important in homeostasis of the endovascular volume by intergrading physiology of the heart, vessels and kidneys. It promotes natriuresis, vasodilation and suppresses the action of the renin- angiotensin system. It is elevated in arterial hypertension and particular in LVH. It relates to cardiovascular morbidity. Interleukins (ILs) are signalizing cytokines usually camouflaged in immune cells as macrophages and monocytes. Their concentration may rise in states of inflammation but there are not inflammation markers as high sensitivity CRP (hs-CRP). However, some may exhibit pleiotropic properties and a cardioprotective role. Cardiopulmonary exercise test (CPx) besides classical parameters estimated by a stress test as blood pressure and work load provides the valuable information of the peak O2 consumption during exercise. This is probably the most reliable measure of exercise tolerance. Ramipril is a long action angiotensin converting enzyme inhibitor that regresses LVH and prolongs life in patients with heart failure. It is well tolerated and treats successfully as monotherapy hypertension of stage I or II. Data report that ramipril action on LVH appears beyond a six months therapy. Purpose: To investigate changes in blood pressure, left ventricular mas index (LVMI), MMPs, TIMP1, ILs , hs-CRP and their effects in exercise tolerance ( CPx) in hypertension mediated LVH population within 6 month therapy with ramipril. Method: 50 patients (mean age: 62,4 yo, mean BP: 142/88 mmHg, 21 females, 29 males) with newly diagnosed essential arterial hypertension and concomitant LVH enrolled the study. They had no history of diabetes mellitus, recent infection or any kind of inflammatory disease. They were no smokers, never received therapy for arterial hypertension and have a normal renal function (Cockcroft-Gault formula). All underwent a 2D echocardiography detailed examination for estimation of left ventricular mass index (LVMI by the Deveraux formula) and relative wall thickness (RWT). Coronary artery disease was excluded y coronary angiography. Blood samples to determine MMP2, MMP3, MMP9, TIMP1, IL2, IL3, hs-CRP and NTpro BNP were taken. A CPx was performed and a NTpro BNP sample was taken right after. Then all received ramipril as antihypertensive mono therapy targeting blood pressure levels < 140/90 mmHg. Of those 50 patients, 48 ( 96%) received 5 mg of ramipril daily and only 2 (4%) 10mg of ramipril daily in one dose. Six months later the same laboratory , echocardiographic and CPx measurements were performed. As control group we included 39 patients with newly diagnosed arterial hypertension and no LVH. Blood samples to determine MMP2, MMP3, MMP9 were taken. Results: The control and the LVH before therapy groups were not different regarding age, gender, SBP, pulse pressure (PP) , mean pressure (meanP) and the MMP9 and MMP3 levels (p>0,05). The LVH group had a higher mean diastolic blood pressure (DBP) and a lower MPP2 level comparing to the control group ( p<0,05).After a 6 month rampril therapy the LVH group had lower SBP, PP, mean P , LVMI, RWT, NT pro B NP after exercise and TIMP-1 levels l and higher peak VO2 levels (all p<0,05) . MMP2, MMP3 , IL2, IL6 were higher after therapy and MMP9 and hs-CRP were lower ( p>0,05).In bivariate analysis there was a statistical positive correlation between SBP, PP, mean P, LVMI , RWT and the male gender ( p<0,05). Relations remained significant after linear regression analysis including age and BSA. Moreover NTproBNP was related to the PP and age (p<0,05).In order to determine if changes in MMPs and ILs relate to parameters of blood pressure as SBP,PP, meanP we performed bivariate analysis, with no findings suggesting such correlation. There was only a positive relation of LVMI and MMP9 (p<0,05). In linear regression analysis such correlation looses statistical power when parameters of blood pressure interfere. Conclusion: Ramipril 6 month therapy successfully reduced blood pressure and consequently LVMI and RWT in patients with arterial hypertension and concomitant LVH. Moreover it induced structural changes in MMPs ,TIMP1, IL and hs-CRP concentration independently of the blood pressure load. Those changes benefit exercise tolerance as estimated by the CPx test.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Angelis, Athanasios
  • Αγγελής, Αθανάσιος

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/53922

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Angelis, Athanasios; Αγγελής, Αθανάσιος. Κλινικές και δομικές μεταβολές μετά από θεραπευτική παρέμβαση με αναστολέα του μετατρεπτικού ενζύμου της αγγειοτασίνης στην υπερτροφία αριστεράς κοιλίας λόγω υπέρτασης. National and Kapodistrian University of Athens, 2023. http://hdl.handle.net/10442/hedi/53922